Comparison Overview

UCB

VS

Intas Pharmaceuticals

UCB

Allée de la Recherche, 60, Brussels, BE
Last Update: 2025-12-10
View Profile
Between 800 and 849
http://www.ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. We act with thoughtful intent to ensure our work reflects the voices of those we serve. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 12,309
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

Intas Pharmaceuticals

Sarkhej Gandhinagar Highway, Near Sola Bridge, Ahmedabad, Gujarat, IN
Last Update: 2025-12-11
Between 750 and 799
https://intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 18,700
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/ucb-pharma.jpeg
UCB
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/intas-pharmaceuticals.jpeg
Intas Pharmaceuticals
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
UCB
100%
Compliance Rate
0/4 Standards Verified
Intas Pharmaceuticals
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for UCB in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Intas Pharmaceuticals in 2025.

Incident History — UCB (X = Date, Y = Severity)

UCB cyber incidents detection timeline including parent company and subsidiaries

Incident History — Intas Pharmaceuticals (X = Date, Y = Severity)

Intas Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/ucb-pharma.jpeg
UCB
Incidents

No Incident

https://images.rankiteo.com/companyimages/intas-pharmaceuticals.jpeg
Intas Pharmaceuticals
Incidents

No Incident

FAQ

UCB company demonstrates a stronger AI Cybersecurity Score compared to Intas Pharmaceuticals company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Intas Pharmaceuticals company has disclosed a higher number of cyber incidents compared to UCB company.

In the current year, Intas Pharmaceuticals company and UCB company have not reported any cyber incidents.

Neither Intas Pharmaceuticals company nor UCB company has reported experiencing a ransomware attack publicly.

Neither Intas Pharmaceuticals company nor UCB company has reported experiencing a data breach publicly.

Neither Intas Pharmaceuticals company nor UCB company has reported experiencing targeted cyberattacks publicly.

Neither UCB company nor Intas Pharmaceuticals company has reported experiencing or disclosing vulnerabilities publicly.

Neither UCB nor Intas Pharmaceuticals holds any compliance certifications.

Neither company holds any compliance certifications.

Intas Pharmaceuticals company has more subsidiaries worldwide compared to UCB company.

Intas Pharmaceuticals company employs more people globally than UCB company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither UCB nor Intas Pharmaceuticals holds SOC 2 Type 1 certification.

Neither UCB nor Intas Pharmaceuticals holds SOC 2 Type 2 certification.

Neither UCB nor Intas Pharmaceuticals holds ISO 27001 certification.

Neither UCB nor Intas Pharmaceuticals holds PCI DSS certification.

Neither UCB nor Intas Pharmaceuticals holds HIPAA certification.

Neither UCB nor Intas Pharmaceuticals holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

LibreChat is a ChatGPT clone with additional features. In versions 0.8.0 and below, there is no handler for JSON parsing errors; SyntaxError from express.json() includes user input in the error message, which gets reflected in responses. User input (including HTML/JavaScript) can be exposed in error responses, creating an XSS risk if Content-Type isn't strictly enforced. This issue does not have a fix at the time of publication.

Published
Date
2025-12-11
Updated
Date
2025-12-11
Risk Information
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:L/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

LibreChat is a ChatGPT clone with additional features. In versions 0.8.0 and below, when creating prompts, JSON requests are sent to define and modify the prompts via PATCH endpoint for prompt groups (/api/prompts/groups/:groupId). However, the request bodies are not sufficiently validated for proper input, enabling users to modify prompts in a way that was not intended as part of the front end system. The patchPromptGroup function passes req.body directly to updatePromptGroup() without filtering sensitive fields. This issue is fixed in version 0.8.1.

Published
Date
2025-12-11
Updated
Date
2025-12-11
Risk Information
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:L/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

LibreChat is a ChatGPT clone with additional features. In versions 0.8.0 and below, when a user posts a question, the iconURL parameter of the POST request can be modified by an attacker. The malicious code is then stored in the chat which can then be shared to other users. When sharing chats with a potentially malicious “tracker”, resources loaded can lead to loss of privacy for users who view the chat link that is sent to them. This issue is fixed in version 0.8.1.

Published
Date
2025-12-11
Updated
Date
2025-12-11
Risk Information
cvss4
Base: 8.6
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:H/VI:H/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

MaxKB is an open-source AI assistant for enterprise. Versions 2.3.1 and below have improper file permissions which allow attackers to overwrite the built-in dynamic linker and other critical files, potentially resulting in privilege escalation. This issue is fixed in version 2.4.0.

Published
Date
2025-12-11
Updated
Date
2025-12-11
Risk Information
cvss3
Base: 8.8
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
References
Description

MaxKB is an open-source AI assistant for enterprise. In versions 2.3.1 and below, the tool module allows an attacker to escape the sandbox environment and escalate privileges under certain concurrent conditions. This issue is fixed in version 2.4.0.

Published
Date
2025-12-11
Updated
Date
2025-12-11
Risk Information
cvss3
Base: 8.8
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
References